Compare Futu Holdings Ltd (FUTU) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Medpace Holdings Inc — how do they compare? Futu Holdings Ltd trades at $113.54 (market cap $15.25B), while Medpace Holdings Inc trades at $616.83 (market cap $16.82B). The key difference: Futu Holdings Ltd and Medpace Holdings Inc are close in size by market cap, and Futu Holdings Ltd pays a 2.39% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Medpace Holdings Inc for 14 Days on average.
| FUTU | MEDP | |
|---|---|---|
Market Cap | $15.25B | $16.82B |
Volume | 812,567 | 223,093 |
Sector | Financials | Health |
52-Week High | $199.04 | $630.19 |
52-Week Low | $89.76 | $393.42 |
Typical Hold Time | 34 Days | 14 Days |
Enterprise Value | $15.59B | $16.44B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings trades at $113.52, up 3.5% in the last session. The stock exhibits strong fundamentals with a P/E of 10.86 and net income margin of 42.92%, though technical indicators signal a bearish trend. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1 2026. The company's Moomoo platform continues expanding globally, with new partnerships and marketing initiatives driving user growth.
Outlook remains positive due to robust profitability and overseas expansion, but risks include ongoing securities class action lawsuits and competitive pressures. Analyst consensus is bullish with a 58.3% buy rating, projecting significant upside potential from current levels.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
